



12780 El Camino Real, San Diego, CA 92130 (858) 617-7600

June 3, 2021

Dear Vermont Attorney General's Office,

As required by 18 V.S.A. § 4637(b), Neurocrine Biosciences, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on June 1, 2021. The new product being launched is:

Product Name: INGREZZA<sup>®</sup> (valbenazine) 60 mg capsules  
NDC: 70370-1060-01

Sincerely,

*Ingrid M. Brewer*

Ingrid M. Brewer  
Sr. Manager, Contracts, Pricing & Trade  
Neurocrine Biosciences, Inc.